Jornal Vascular Brasileiro
https://app.periodikos.com.br/journal/jvb/article/doi/10.1590/1677-5449.180109
Jornal Vascular Brasileiro
Original Article

HDL-C and non-HDL-C levels are associated with anthropometric and biochemical parameters

Associação de níveis de HDL-c e não HDL-c com parâmetros antropométricos e bioquímicos

Sandra Maria Barbalho; Ricardo José Tofano; Marcela Bueno de Oliveira; Karina Rodrigues Quesada; Mariana Ricci Barion; Marina Cristina Akuri; Marie Oshiiwa; Marcelo Dib Bechara

http://dx.doi.org/10.1590/1677-5449.180109 J Vasc Bras, vol.18, e20180109, 2019
PDF
SciELO
Downloads: 1
Views: 1902

Abstract

Abstract: Background: Dyslipidemias are associated with atherosclerosis and cardiovascular diseases. Recently, non-high-density lipoprotein cholesterol (non-HDL-c) has emerged as a new target for assessment and prediction of risk of cardiovascular disease (CVD) and is closely associated with atheroma plaque progression.

Objectives: To evaluate associations between HDL-c and non-HDL-c levels and anthropometric and biochemical parameters and with the Castelli risk indexes I and II.

Methods: 300 randomly selected people were subdivided into two groups: patients with normal values for non-HDL-c and patients with altered values for non-HDL-c. These parameters were analyzed for associations with glycemia, total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-c), Castelli Index I (CI-I), Castelli Index II (CI-II), waist circumference (WC), body mass index (BMI) and presence of metabolic syndrome (MS).

Results: Glycemia, TC, TG, LDL-c, CI-I, CI-II, WC and BMI were all significantly different between subjects with normal and altered values of HDL-c and non-HDL-c. TC and WC both exhibited significantly higher values among patients with abnormal non-HDL-c when compared to patients with abnormal HDL-c. A significant difference was observed in occurrence of MS among patients with altered values of HDL-c and non-HDL-c.

Conclusions: Our results show that both HDL-c and non-HDL-c are associated with insulin resistance, dyslipidemia, atherogenic indices, and obesity. There is therefore a need for randomized clinical intervention trials examining the potential role of non-HDL-c as a possible primary therapeutic target.

Keywords

non-HDL-c, glycemia, dyslipidemia, metabolic syndrome

Resumo

Resumo: Contexto: A dislipidemia está associada à aterosclerose e às doenças cardiovasculares. Recentemente, a lipoproteína de não alta-densidade de colesterol (não HDL-c) emergiu como um novo alvo para avaliação da predição de risco de doença cardiovascular, intimamente associada à progressão da placa de ateroma.

Objetivos: Avaliar as associações de níveis de HDL-c e não HDL-c com parâmetros antropométricos e bioquímicos, bem como com índices de Castelli I e II (CI-I e CI-II).

Métodos: Trezentas pessoas selecionadas aleatoriamente foram divididas em dois grupos: pacientes com valores normais de não HDL-c e pacientes com valores alterados de não HDL-c. Esses parâmetros foram associados a glicemia, colesterol total (CT), triglicerídeos (TG), lipoproteína de baixa densidade (LDL-c), CI-I, CI-II, circunferência de cintura (CC), índice de massa corporal (IMC) e presença de síndrome metabólica (SM).

Resultados: Glicemia, CT, TG, LDL-c, CI-I, CI-II, CC e IMC exibiram valores significativamente maiores para o não HDL-c quando comparado ao HDL-c. Uma diferença significativa na ocorrência de SM foi encontrada em pacientes com valores alterados de HDL-c e não HDL-c.

Conclusões: Nossos resultados mostram que tanto o HDL-c quanto o não HDL-c estão associados a resistência à insulina, dislipidemia, índices de aterogênese e obesidade. Assim, há uma necessidade de futuros ensaios randomizados de intervenção clínica examinando o papel potencial do não HDL-c como possível alvo terapêutico primário.
 

Palavras-chave

não HDL-c, glicemia, dislipidemia, síndrome metabólica

References

Barbalho S, Tofano RJ, Bechara MD, Quesada K, Coqueiro DP, Mendes CG. Castelli Index and estimative of LDL-c particle size may still help in the clinical practice? J Cardiovasc Dis Res. 2016;7(2):86-9. http://dx.doi.org/10.5530/jcdr.2016.2.6.

Alibasic E, Ramic E, Bajraktarevic A, Ljuca F, Batic-Mujanovic O, Zildzic M. Atherogenic dyslipidemia and residual vascular risk in practice of family doctor. Med Arh. 2015;69(5):339-41. http://dx.doi.org/10.5455/medarh.2015.69.339-341. PMid:26622090.

Costa IFAF, Medeiros CCM, Costa FDAF, et al. Adolescentes: comportamento e risco cardiovascular. J Vasc Bras. 2017;16(3):205-13. http://dx.doi.org/10.1590/1677-5449.011816. PMid:29930648.

Puri R, Nissen SE, Shao M, et al. Non-HDL cholesterol and triglycerides: Implications for coronary atheroma progression and clinical events. Arterioscler Thromb Vasc Biol. 2016;36(11):2220-8. http://dx.doi.org/10.1161/ATVBAHA.116.307601. PMid:27515380.

Zeb I, Budoff M. Coronary Artery calcium screening: does it perform better than other cardiovascular risk stratification tools? Int J Mol Sci. 2015;16(3):6606-20. http://dx.doi.org/10.3390/ijms16036606. PMid:25807266.

Faludi AA, Izar MCO, Saraiva JFK, et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose - 2017. Arq Bras Cardiol. 2017;109(2, Suppl 1):1-76.

Grundy SM. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. J Clin Lipidol. 2013;7(6):561-5. http://dx.doi.org/10.1016/j.jacl.2013.10.001. PMid:24314355.

Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1- full report. J Clin Lipidol. 2015;9(2):129-69. http://dx.doi.org/10.1016/j.jacl.2015.02.003. PMid:25911072.

Ghodsi S, Meysamie A, Abbasi M, et al. Non-high-density lipoprotein fractions are strongly associated with the presence of metabolic syndrome independent of obesity and diabetes. A population-based study among Iranian adults. J Diabetes Metab Disord. 2017;25(1):16-25. http://dx.doi.org/10.1186/s40200-017-0306-6. PMid:28596946.

Fruchart JC, Davignon J, Hermans MP, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13(1):26. http://dx.doi.org/10.1186/1475-2840-13-26. PMid:24460800.

Wang D, Wang L, Wang Z, Chen S, Ni Y, Jiang D. Higher non-HDL-cholesterol to HDL-cholesterol ratio linked with increased nonalcoholic steato hepatitis. Lipids Health Dis. 2018;17(1):67. http://dx.doi.org/10.1186/s12944-018-0720-x. PMid:29615042.

Bermúdez V, Torres W, Salazar J, et al. Non-HDL cholesterol is better than LDL-c at predicting atherosclerotic cardiovascular disease risk factors clustering, even in subjects with near-to-normal triglycerides: A report from a Venezuelan population. F1000 Res. 2018;7:504. http://dx.doi.org/10.12688/f1000research.13005.1.

Kumar VB, Guntakalla YR, Thomas Z, Rajasekaran UR, Gnanasekaran P. Role of Non High Density Lipoprotein Cholesterol (Non HDL-C) in predicting coronary artery disease. Indian J Pharmacy Practice. 2015;8(4):166-70. http://dx.doi.org/10.5530/ijopp.8.4.4.

Moriyama K, Takahashi E. Non-HDL Cholesterol is a more superior predictor of small-dense LDL Cholesterol than LDL Cholesterol in japanese subjects with TG levels <400 mg/dL. J Atheroscler Thromb. 2016;23(9):1126-37. http://dx.doi.org/10.5551/jat.33985. PMid:27001003.

Kim SW, Jee JH, Kim HJ, et al. Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1. Int J Cardiol. 2013;168(3):2678-83. http://dx.doi.org/10.1016/j.ijcard.2013.03.027. PMid:23545148.

Gasevic D, Frohlich J, Mancini GJ, Lear SA. Clinical usefulness of lipid ratios to identify men and women with metabolic syndrome: a cross-sectional study. Lipids Health Dis. 2014;13(1):159. http://dx.doi.org/10.1186/1476-511X-13-159. PMid:25300321.

Huang J, Parish R, Mansi I, et al. Non-high-density lipoprotein cholesterol in patients with metabolic syndrome. J Investig Med. 2008;56(7):931-6. http://dx.doi.org/10.2310/JIM.0b013e318182080a. PMid:18753978.

Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty Acid-Binding Protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin Med Insights Cardiol. 2015;8(Suppl 3):23-33. http://dx.doi.org/10.4137/CMC.S17067. PMid:25674026.

Ruan Y, Wei W, Yan J, et al. Time rate of blood pressure variation is associated with Endothelial Function in patients with metabolic syndrome. Int Heart J. 2016;57(2):226-33. http://dx.doi.org/10.1536/ihj.15-322. PMid:26973261.

Kurkowska-Jastrzebska I, Karlinski MA, Błazejewska-Hyzorek B, Sarzynska-Dlugosz I, Filipiak KJ, Czlonkowska A. Carotid intima media thickness and blood biomarkers of atherosclerosis in patients after stroke or myocardial infarction. Croat Med J. 2016;57(6):548-57. http://dx.doi.org/10.3325/cmj.2016.57.548. PMid:28051279.

Panazzolo DG, Sicuro FL, Clapauch R, Maranhão PA, Bouskela E, Kraemer-Aguiar LG. Obesity, metabolic syndrome, impaired fasting glucose, and microvascular dysfunction: a principal component analysis approach. BMC Cardiovasc Disord. 2012;12(1):102. http://dx.doi.org/10.1186/1471-2261-12-102. PMid:23148545.

Kraemer-Aguiar LG, Miranda ML, Bottino DA, et al. Increment of body mass index is positively correlated with worsening of endothelium-dependent and independent changes in forearm blood flow. Front Physiol. 2015;6:223. http://dx.doi.org/10.3389/fphys.2015.00223.
 

Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)"> Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)">
5cacf1090e8825cf25fa9a2c jvb Articles
Links & Downloads
1677-7301 (Electronic)
J Vasc Bras ©2024 All rights reserved.

J Vasc Bras

Share this page
Page Sections